Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Brazil CV-19 is raging PDSB updates on the CV-19 Funding from brazil government is coming so are cancer updates in a few months. Second generation CV-19 vaccines are a going to be imperative PDSB has the platform for CV-19 variants. I like the focus on south America very smart by management.
$PDSB
The MM blocking crew trying too hard...watch what happens next!
Institutional ownership getting close to 60% in 2 months in 2021 with the most current 13Gs up from 7% late last year.
SAD Social Anxiety disorder Phase 3 Fast tracked first ever for SAD by the FDA.
Multiple phase 2's.
105 million in cash.
VTGN next generation Depression Anxiety meds.
close to 50% of adults polled say they have depression & or anxiety.
VTGN 2021 Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 1.7 billion market cap very early clinical trials. 170 million cash
$MMEDF 1.1 billion market cap. Phase 2
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 333 million market cap Phase 3 ready. (nasdaq)
105 million in cash
$VTGN
VTGN Phase 3 For SAD (social anxiety disorder starts soon) Fast tracked.
This phase 3 clinical trial is designed to evaluate efficacy, safety and tolerability. Subject participation will last a total to 3-7 weeks. Trial is being Lead by michael leibowitz inventor of the Leibowitz social anxiety scale.
Surveys are finding that rates of anxiety and depression & other mental illness. Are still well above pre pandemic levels among American adults with 43.1% of those surveyed claiming at least one mental health issue.
https://www.physiciansweekly.com/anxiety-depression-remain-elevated-well-into-covid-19-pandemic/
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Lot's of pent up demand for Anxiety and depression drugs that are fast acting and have low side effects. SSRi's work less than 30% time with massive side effects and takes months for the medication to kick in thats where VTGN comes into play a total disruptor in the multi billion dollar space. VTGN institutions ownership has risen to close to 60% as of today from last year under 10%.
VTGN 105 million in cash
$VTGN
Back in 38.09 sell order at 62.00.
RKT is gme 2.0
Thank you shorties.
$RKT
Invest in the dip...... this stock is under accumulation and I could see it breaking out higher.
Adding huge on the dip. Stock traded at $3.18 recently. Primed to double in price soon!
Get your shares and hold them. Lock them up GTC sky high.
Phase 3 is where the rubber meets the road.
THERE IS A TIGER RAGING INSIDE HER CAGE, & SHE'S GOING TO BREAK HER CHAINS AND SCREAM THROUGH THE JUNGLE, THIS WILL CREATE THUNDER BEYONG WHAT WE HAVE EVER SEEN.
VistaGen just initiated with Buy at Jefferies on 'upside potential' for anxiety drug $6.00-8.00 Target this year.
Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5
b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 1.7 billion market cap early clinical trials. 190 million cash
$MMEDF 1.1 billion market cap.
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 315 million market cap Phase 3 ready. (nasdaq)
115 million in cash
$VTGN
Solid powercrush chart looked good to me in the teens. Dan Gilbert has founded a great company.
$RKT
In $27.32 13k shares out $35.97
Rocket man Shout out to my reddit crew. Thanks for the heads up.
$RKT
Only stock I flip & add to the core positions thank you again Reddit army & Ihub forces.
Burn shorties for a living!
special shout out to my friend roaring kitty.
$GME
Love destroying the shorties Feeling da pain. And I'm seeing magnificent gains.
$MARA
What a beast.
Loaded to the gills.
$IDEX
I will say it one more time this is my pick of the year.
Time to Gamestop these Shorts & Squeeze them to their demise.
Massive hammers the company is about to drop.
Next generation depression & anxiety meds fast acting low side effects!
Diamond Hands!!
https://giphy.com/gifs/filmeditor-movie-comedy-3o7buiQeyYFamzRoR2
$VTGN
Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A
Know what you own this stock can move hundreds of percentage points on the catalysts listed below.
institutional ownership has sky rocketed this year now close to 60% as medical focused hedge funds keep filing their new ownership in VTGN
This my number 1 core holding I'm investing in mental health and like how this company is creating drugs that are fast acting and have very low side effects compared to the standard of care today which only works SSRI's 20-30% of time takes months to work and has extremely high side effects. These are multi billion dollar markets company very likely could get bought like Sage where Biogen bought them out for 1.5 Billion last year.
Reality is a quarter to half the worlds population is suffering from Depression & Anxiety! Vistagen is a disruptor for the industry and a multi billion dollar market cap in the making by next year. Just load up and hold for 12-24 months that way when you sell you pay way less on taxes. Thats what I'm doing with VTGN I own close to 500K shares across multiple accounts and will keep buying I made millions this last year. And will make millions on this particular investment. You can make book on that!
VTGN is almost a lock to be at $10 by end of year. Great CEO, excellent leadership, smart execution of their plan and a great product on the horizon! PH94B. And evidenced by their solid stock price on a very down day.
I have had multiple discussions with Mark McPartland VP of corporate development. I have done my DD on this stock. Anyone who is in now and sells below $20 is a fool. This stock will make you a lot of money if you’re patient. PH94B is the real deal.
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 1.7 billion market cap early clinical trials. 190 million cash
$MMEDF 1.1 billion market cap.
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 315 million market cap Phase 3 ready. (nasdaq)
115 million in cash
$VTGN
Copy That This company is set up to flourish in the future!
$IDEX
I got my shares locked & keyed.
Off to play some golf ladies & gentlemen get out of the house & get some fresh air and let these market makers play with themselves.
$PDSB
Did buy 150k more in the 3.00's my average is way lower started buying near the lows last year Average low $1.00's thanks for your concern LOL LMAO.
$IDEX
Starting buying at $15.00 Will add if it dips into the low 80.00s again.
I have no problem adding the dips and buying quality stocks for the long term.
$BEAM
Just keep trading this and doing really well and adding to my core small cap biotech holdings Thank you again roaring kitty when he said he doubles his stash in GME shares not long ago thats when I started trading this again.
$GME
I started buying this stock at .33 my average price is now $1.11
I will add more if she dips.
Warren Buffett has said, "The stock market is a device for transferring money from the impatient to the patient.
$IDEX
Patience is key here MM are toying with the impatient investor looking to make a quick buck. Turbulent market. Small cap Biotechs are the place to be invested. Medical breakthroughs can quantum leap hundreds sometimes thousands of percentage points. PDSB is very undervalued at these levels.
3 Phase 2 Cancer trials with top cancer organizations Mc Anderson NIH & MERCK.
Development of PDS0203 - A second generation COVID-19 vaccine that
promotes powerful T-cell responses and neutralizing antibodies
clinical studies show powerful induction of long-lasting polyfunctional CD8+ and
CD4+ anti-SARS-CoV-2 T-cells
PDSB Feb 2021 Biz presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Feb_2021_FINAL.pdf
PDSB Website:
https://www.pdsbiotech.com/
Warren Buffett has said, "The stock market is a device for transferring money from the impatient to the patient.
$PDSB
Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development FAST TRACKED
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia
3. Preparing for Phase 2A program
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A
Know what you own this stock can move hundreds of percentage points on the catalysts listed below.
This my number 1 core holding I'm investing in mental health and like how this company is creating drugs that are fast acting and have very low side effects compared to the standard of care today which only works SSRI's 20-30% of time takes months to work and has extremely high side effects. These are multi billion dollar markets company very likely could get bought like Sage where Biogen bought them out for 1.5 Billion last year.
Reality is a quarter to have the worlds population is suffering from Depression & Anxiety! Vistagen is a disruptor for the industry and a multi billion dollar market cap in the making by next year. Just load up and hold for 12-24 months that way when you sell you pay way less on taxes. Thats what I'm doing with VTGN I own close to 500K shares across multiple accounts and will keep buying I made millions this last year. And will make millions on this particular investment. You can make book on that!
don’t say this often, but VTGN is almost a lock to be at $10 by end of year. Great CEO, excellent leadership, smart execution of their plan and a great product on the horizon! PH94B. And evidenced by their solid stock price on a very down day.
I have had multiple discussions with Mark McPartland VP of corporate development. I have done my DD on this stock. Anyone who is in now and sells below $20 is a fool. This stock will make you a lot of money if you’re patient. PH94B is the real deal.
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 1.7 billion market cap early clinical trials. 190 million cash
$MMEDF 1.1 billion market cap.
$SAGE 5 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 315 million market cap Phase 3 ready. (nasdaq)
115 million in cash
$VTGN
This last week VistaGen Therapeutics initiated by Jefferies Financial Group Inc. at buy. $6.00 PT within 12 months they know their research well. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. In this case, Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B.
Took my GME profits from yesterday and today and added more VTGN
another 77k shares added yesterday.
A disruptive Depression and anxiety next generation meds low side effects and fast acting. This is now my largest holding Thanks for the cheapies 2.24-2.26 filled today much appreciated. Phase 3 multiple Phase 2'a enough cash to fund SAD Social anxiety Disorder across the finish line. 16 drug indications in their pipeline. They will get bought out most likely Like Biogen bought SAGE 1/3'1/2 the population suffering from Depression and anxiety.
Biogen Bets $1.5 Billion on Sage Therapeutics' Drug for Depressive Disorders.
https://www.biospace.com/article/biogen-makes-1-5-billion-bet-on-depression-treatments-under-development-by-sage-therapeutics/
COVID-19 disrupting mental health services in most countries, WHO survey World Mental Health Day to highlight urgent need to increase investment in chronically underfunded sector..
The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey. The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.
https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash
Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.
93% increase in people participating in anxiety screenings, according to Mental Health America.
Study finds Colorado has 31% average rate of depression and anxiety.
https://www.denverpost.com/2021/02/18/mental-health-colorado-pandemic-anxiety-depression/
$VTGN
Traded it 9x last 24 hours for 163k Profit thank you Roaring Kitty Meow Meow
Bought some calls 60 days out if it continues to surge I will make more Lets burn those shorties to the ground.
https://www.pinterest.com/pin/740208888727857367/
$GME
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
SINT my 1.78's are golden
$SINT
Bought another 50k today 150k Long average price 3.42
$IDEX
In heavy here lets see some new 52 week highs shane mcmahon is a big investor here I likey.
$IDEX
My top pick from here on out.
https://ideanomics.com/company-portfolio/
https://ideanomics.com/about-us/
https://ideanomics.com/
$IDEX
Added a 100k shares today lets do this 5G EV Blockchain Play I likey .
$IDEX
holding strong and Long john what shix they pull here clearly they want all the shares they can get that means one thing they already know this will be big!
a supernova in the making!!
Hold on to your shares an set sell limits high its worth it
set inbetween 6- 20-50-and 100
added 27K thanks again CLOWNS
$VTGN
All wee need is a little ask slapping here pick up the volume.
$PDSB
Hold the Line!
https://giphy.com/gifs/hold-braveheart-brave-heart-62HIkemjJZOD95NDlI
$PDSB
Should break New Highs soon if you sold earlier you got robbed for your shares call the police. The police won't come and save you The police have been defunded. Wave 3 in the Elliot wave should see way higher prices from here.
This company is combating mental illness with fast acting low side effects Depression & Anxiety drugs half the population is depressed and has lots of anxiety Hello Bueller anyone home! Phase 3 Company might get bought out for billions like SAGE we have better drugs and deeper pipeline Sage just got bought out by Biogen for 3 Billion not that long ago. 16 drugs in the pipeline that is now funded.
shorts are screwed let's slap that ask and make them pay Squeeze those clowns trying to short a company fighting mental illness they must pay with their pocket books and teach these toothless buffoons a lesson lets REKT these clowns once and for all.
VTGN FEED ME:
https://giphy.com/gifs/bbcamerica-bbc-america-seven-worlds-one-planet-IbaTs1YZ9QLDpr8a6U
Lets Go:
https://giphy.com/gifs/drake-lets-go-S5yqNNTQlEZfqQ7InC
Victorious
https://giphy.com/gifs/padres-lets-go-come-on-do-this-OkSh6YXYJZGtwd84ZK
Bulls all the way Bears RIP
https://giphy.com/gifs/pbr-high-school-rodeo-nhsra-YT805t3TRDy6uISZuN
Hold the Line fight fire with fire:
https://giphy.com/gifs/hold-braveheart-brave-heart-c16VH0CFMh7gOqqXOM
$VTGN
VTGN Looking beyond the standard
of care for anxiety, depression
and other CNS disorders.
Phase 3 is where the rubber meets the road. And market cap starts to exponential move.
VTGN 115 million plus cash in the bank.
VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year.
Cash runway into 2023 Till product gets Approved
VTGN Phase 3 ready Fast tracked. Social Anxiety Disorder multi billion dollar market
Multiple phase 2's including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment.
World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU
Acceleration Program (CTAP)
Investment Highlights.
Three Differentiated Clinical-Stage CNS Drug
Candidates.
• Novel Mechanisms of Action (MOAs).
• Favorable Safety Results in All Studies to Date.
• Therapeutic Potential for Phase 3 depression drug in Large Global Mental.
Health and Neurology Markets.
• Multiple NDA-Enabling and Phase 2 Clinical
Catalysts.
• Growing Global Partnership and Licensing Interest.
Anxiety Disorders
PH94B
Depression Disorders
PH10
Neurological Disorders
AV-101
Three differentiated clinical-stage CNS drug candidates
each with a novel mechanism of action, favorable
safety results in all studies to date, and therapeutic
potential in multiple large therapeutic indications
Potential to be a first-in-class, fast-acting, acute treatment of
anxiety for adults with Social Anxiety Disorder and several
other anxiety disorders with inadequate treatment options
Potential stand-alone rapid-onset antidepressant
without side effects and safety concerns of ketaminebased therapy
Potential oral NMDAR-focused prodrug for depression and
multiple neurological indications with adjunctive probenecid.
16 indications in the Pipeline:
https://www.vistagen.com/pipeline
VTGN Anticipated Study Catalysts:
1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development.
2. AffaMed Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia.
3. Preparing for Phase 2A program.
4. Assessing for potential Phase 2A program
5. Successful Phase 2A program completed; preparing for Phase 2B program
6. Assessing for Phase 1B to support potential Phase 2A
Social Anxiety Disorder Affects as many as
20 million people just in the USA
giving a speech
meeting new people
presenting at work
eating/drinking in front of others
interviewing for a job
Current Standard of Care for SAD is Inadequate
Limited treatment options highlight significant unmet need
No FDA-Approved, Fast-Acting, As-Needed Treatment for SAD
Antidepressants (2 SSRIs, 1 SNRI)
Slow onset, chronic administration
May worsen anxiety initially
Significant potential side effects
Nausea and vomiting, weight gain,
somnolence and sexual
dysfunction
Potential drug-drug interaction
Benzodiazepines, Beta Blockers
Addiction risk
Significant potential side effects
Nausea and vomiting, blurred
vision, dizziness, sedation,
confusion and cognitive
impairment
Oral Antidepressants:
• Often do not work; slow to work
– Initial ADT effective in 1 of 3 patients1
– May take 4 to 6 weeks or more for
antidepressant effects
• Significant potential side effects
– Anxiety, sexual dysfunction,
insomnia, dizziness, nausea and
vomiting, headache, sweating
VTGN looking to disrupt depression and anxiety markets globally tens of billions in potential revenue.
VTGN Presentation 2021
https://d1io3yog0oux5.cloudfront.net/_ae1a415cb3c61248d04df87a65dbdb13/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+Version+2021_02_02.pdf
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash
Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.
VTGN 56 million shares traded up from $2.00=$3.18 2 days late last week.
VTGN 16.5 million shares traded last 2 days down from 3.18-2.05 this monday and Tuesday.
VistaGen initiated with Buy at Jefferies $6.00-$8.00 this year 6 days ago.
Buying this stock is helping to fight mental illness anyone shorting this stock is going to lose!!!
$VTGN
MARA investors no matter if storm or snow, we stay on course.
Shorts are getting REKT.
$MARA
no matter if storm or snow, we stay on course
$PDSB
Shawn Singh of VistaGen Therapeutics: 5 Ways That Businesses Can Help Promote The Mental Wellness Of Their Employees.
https://medium.com/authority-magazine/shawn-singh-of-vistagen-therapeutics-5-ways-that-businesses-can-help-promote-the-mental-wellness-21e423b99435
$VTGN
added 55k on the dip thank you!!!!
lots of hammers and catalysts VTGN about to drop on the Shorts cranium. Lets REKT these clowns!
If you sold today you got Robbed for your shares!
VTGN 50 million shares traded up from $2.00=$3.18
VTGN 16.5 million shares traded last 2 days down from 3.18-2.05
$VTGN
Copy that lets REKT those shorts
$PDSB
HOLD THE LINE!
https://tenor.com/view/braveheart-hold-shouts-gif-13268605
$PDSB